Is there a therapeutic window of opportunity in early inflammatory bowel disease? Early stage inflammatory bowel disease: The actual management

Minerva Gastroenterologica e Dietologica

Volumn 59, Issue 3, 2013, Pages 299-312

  Kevans, D ^a   Van Assche, G ^a  

^a MOUNT SINAI HOSPITAL   (Canada)

Author keywords

Biological therapy; Immunologic factors; Inflammatory bowel diseases

Indexed keywords

ADALIMUMAB; AZATHIOPRINE; CERTOLIZUMAB PEGOL; CORTICOSTEROID; CYCLOSPORIN; INFLIXIMAB; MERCAPTOPURINE; METHOTREXATE; PLACEBO; PREDNISOLONE; PREDNISONE; SALAZOSULFAPYRIDINE; VEDOLIZUMAB;

BONE EROSION; CLINICAL PRACTICE; COHORT ANALYSIS; COLON MOTILITY; COLON RESECTION; COLORECTAL CANCER; CORTICOSTEROID THERAPY; CROHN DISEASE; DECISION MAKING; DISEASE COURSE; DISEASE DURATION; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG EXPOSURE; DRUG SAFETY; EARLY INTERVENTION; ESCHERICHIA COLI; EVIDENCE BASED PRACTICE; FOLLOW UP; GASTROINTESTINAL HEMORRHAGE; GENETIC SUSCEPTIBILITY; HEALTH CARE QUALITY; HIGH RISK PATIENT; HOSPITALIZATION; HUMAN; ILEUM RESECTION; IMMUNOSUPPRESSIVE TREATMENT; INTESTINE INJURY; JOINT DESTRUCTION; LEUKOPENIA; MAINTENANCE THERAPY; META ANALYSIS; MONOTHERAPY; OPEN STUDY; OSTEOCLAST; OSTEOCLASTOGENESIS; OUTCOME ASSESSMENT; PHENOTYPE; PROSPECTIVE STUDY; PSEUDOMONAS FLUORESCENS; RANDOMIZED CONTROLLED TRIAL (TOPIC); REMISSION; REVIEW; RHEUMATOID ARTHRITIS; RISK ASSESSMENT; RISK FACTOR; SYNOVITIS; T CELL LYMPHOMA; THERAPY DELAY; TIME TO TREATMENT; TOXIC MEGACOLON; TREATMENT DURATION; TREATMENT RESPONSE; ULCERATIVE COLITIS;

ARTHRITIS, RHEUMATOID; EARLY MEDICAL INTERVENTION; HUMANS; IMMUNOSUPPRESSION; INFLAMMATORY BOWEL DISEASES; PROGNOSIS; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX; TIME FACTORS;

EID: 84885057689     PISSN: 1121421X     EISSN: 18271642     Source Type: Journal    
DOI: None     Document Type: Review

References (81)

1. Bernstein CN, Wajda A, Svenson LW, MacKenzie A, Koehoorn M, Jackson M et al. The epidemiology of inflammatory bowel disease in Canada: a population-based study. Am J Gastroenterol 2006;101:1559-68. (Pubitemid 43980630)
2. Loftus EV, Jr. Clinical epidemiology of inflammatory bowel disease: Incidence, prevalence, and environmental influences. Gastroenterology 2004;126:1504-17.
3. Lin MV, Blonski W, Lichtenstein GR. What is the optimal therapy for Crohn's disease: step-up or topdown? Expert Rev Gastroenterol Hepatol 2010;4:167-80.
4. Beaugerie L, Seksik P, Nion-Larmurier I, Gendre JP, Cosnes J. Predictors of Crohn's disease. Gastroenterology 2006;130:650-6. (Pubitemid 43374514)
5. Solberg IC, Vatn MH, Hoie O, Stray N, Sauar J, Jahnsen J et al. Clinical course in Crohn's disease: results of a Norwegian population-based ten-year follow-up study. Clin Gastroenterol Hepatol 2007;5:1430-8. (Pubitemid 350181602)
6. Henriksen M, Jahnsen J, Lygren I, Aadland E, Schulz T, Vatn MH et al. Clinical course in Crohn's disease: results of a five-year population-based follow-up study (the IBSEN study). Scand J Gastroenterol 2007;42:602-10. (Pubitemid 46633816)
7. Thia KT, Sandborn WJ, Harmsen WS, Zinsmeister AR, Loftus EV, Jr. Risk factors associated with progression to intestinal complications of Crohn's disease in a population-based cohort. Gastroenterology 2010;139:1147-55.
8. Cosnes J, Cattan S, Blain A, Beaugerie L, Carbonnel F, Parc R et al. Long-term evolution of disease behavior of Crohn's disease. Inflamm Bowel Dis 2002;8:244-50. (Pubitemid 34784976)
9. Solberg IC, Lygren I, Jahnsen J, Aadland E, Hoie O, Cvancarova M et al. Clinical course during the first 10 years of ulcerative colitis: results from a population-based inception cohort (IBSEN Study). Scand J Gastroenterol 2009;44:431-40.
10. Sjoberg D, Holmstrom T, Larsson M, Nielsen AL, Holmquist L, Ekbom A et al. Incidence and natural history of ulcerative colitis in the Uppsala Region of Sweden 2005-2009 - Results from the IBD cohort of the Uppsala Region (ICURE). J Crohns Colitis 2013 [Epub ahead of print].
11. Farmer RG, Easley KA, Rankin GB. Clinical patterns, natural history, and progression of ulcerative colitis. A long-term follow-up of 1116 patients. Dig Dis Sci 1993;38:1137-46. (Pubitemid 23175139)
12. Targownik LE, Singh H, Nugent Z, Bernstein CN. The epidemiology of colectomy in ulcerative colitis: results from a population-based cohort. Am J Gastroenterol 2012;107:1228-35.
13. Henriksen M, Jahnsen J, Lygren I, Sauar J, Kjellevold O, Schulz T et al. Ulcerative colitis and clinical course: results of a 5-year population-based follow-up study (the IBSEN study). Inflamm Bowel Dis 2006;12:543-50. (Pubitemid 43977734)
14. Turner D, Walsh CM, Steinhart AH, Griffiths AM. Response to corticosteroids in severe ulcerative colitis: a systematic review of the literature and a meta-regression. Clin Gastroenterol Hepatol 2007;5:103-10. (Pubitemid 46096828)
15. Gore RM. Characteristic morphologic changes in chronic ulcerative colitis. Abdom.Imaging 1995;20:275-7.
16. Coulie B, Camilleri M, Bharucha AE, Sandborn WJ, Burton D. Colonic motility in chronic ulcerative proctosigmoiditis and the effects of nicotine on colonic motility in patients and healthy subjects. Aliment Pharmacol Ther 2001;15:653-63. (Pubitemid 32385870)
17. Greig ER, Boot-Handford RP, Mani V, Sandle GI. Decreased expression of apical Na+ channels and basolateral Na+, K+-ATPase in ulcerative colitis. J Pathol 2004;204:84-92. (Pubitemid 39214485)
18. Vrees MD, Pricolo VE, Potenti FM, Cao W. Abnormal motility in patients with ulcerative colitis: the role of inflammatory cytokines. Arch Surg 2002;137:439-45.
19. Beaugerie L, Sokol H. Clinical, serological and genetic predictors of inflammatory bowel disease course. World J Gastroenterol 2012;18:3806-13.
20. Loly C, Belaiche J, Louis E. Predictors of severe Crohn's disease. Scand J Gastroenterol 2008;43:948-54.
21. Wolters FL, Russel MG, Sijbrandij J, Ambergen T, Odes S, Riis L et al. Phenotype at diagnosis predicts recurrence rates in Crohn's disease. Gut 2006;55:1124-30. (Pubitemid 44085679)
22. Cosnes J, Carbonnel F, Beaugerie L, Le Quintrec Y, Gendre JP. Effects of cigarette smoking on the long-term course of Crohn's disease. Gastroenterology 1996;110:424-31. (Pubitemid 26043875)
23. Targan SR, Landers CJ, Yang H, Lodes MJ, Cong Y, Papadakis KA et al. Antibodies to CBir1 flagellin define a unique response that is associated independently with complicated Crohn's diseasE Gastroenterology 2005;128:2020-8.
24. Arnott ID, Landers, CJ, Nimmo EJ, Drummond HE, Smith BK, Targan SR et al. Sero-reactivity to microbial components in Crohn's disease is associated with disease severity and progression, but not NOD2/CARD15 genotypE. Am J Gastroenterol 2004;99:2376-84. (Pubitemid 40039369)
25. Vasiliauskas EA, Kam LY, Karp LC, Gaiennie J, Yang H, Targan SR. Marker antibody expression stratifies Crohn's disease into immunologically homogeneous subgroups with distinct clinical characteristics. Gut 2000;47:487-96.
26. Jostins L, Ripke S, Weersma RK, Duerr RH, McGovern DP, Hui KY et al. Host-microbe interactions have shaped the genetic architecture of inflammatory bowel disease. Nature 2012;491:119-24.
27. Abreu MT, Taylor KD, Lin YC, Hang T, Gaiennie J, Landers CJ et al. Mutations in NOD2 are associated with fibrostenosing disease in patients with Crohn's disease. Gastroenterology 2002;123:679-88. (Pubitemid 34977073)
28. Alvarez-Lobos M, Arostegui JI, Sans M, Tassies D, Plaza S, Delgado S et al. Crohn's disease patients carrying Nod2/CARD15 gene variants have an increased and early need for first surgery due to stricturing disease and higher rate of surgical recurrence. Ann Surg 2005;242:693-700. (Pubitemid 41567125)
29. Vermeire S, Wild G, Kocher K, Cousineau J, Dufresne L, Bitton A et al. CARD15 genetic variation in a Quebec population: prevalence, genotype-phenotype relationship, and haplotype structure. Am J Hum Genet 2002;71:74-83. (Pubitemid 34734709)
30. Devroede GJ, Taylor WF, Sauer WG, Jackman RJ, Stickler GB. Cancer risk and life expectancy of children with ulcerative colitis. N Engl J Med 1971;285:17-21.
31. Lashner BA, Silverstein MD, Hanauer SB. Hazard rates for dysplasia and cancer in ulcerative colitis. Results from a surveillance program. Dig DiSScI 1989;34:1536-1541. (Pubitemid 19255344)
32. Silverberg MS, Satsangi J, Ahmad T, Arnott ID, Bernstein CN, Brant SR et al. Toward an integrated clinical, molecular and serological classification of inflammatory bowel disease: Report of a Working Party of the 2005 Montreal World Congress of Gastroenterology. Can J Gastroenterol 2005;19(Suppl A):5-36.
33. Moum B, Ekbom A, Vatn MH, Aadland E, Sauar J, Lygren I et al. Clinical course during the 1st year after diagnosis in ulcerative colitis and Crohn's disease. Results of a large, prospective population-based study in southeastern Norway, 1990-93. Scand J Gastroenterol 1997;32:1005-12. (Pubitemid 27433664)
34. Langholz E, Munkholm P, Davidsen M, Binder V. Colorectal cancer risk and mortality in patients with ulcerative colitis. Gastroenterology 1992;103:1444-51.
35. Hoie O, Wolters F, Riis L, Aamodt G, Solberg C, Bernklev T et al. Ulcerative colitis: patient characteristics may predict 10-yr disease recurrence in a European-wide population-based cohort. Am J Gastroenterol 2007;102:1692-701.
36. Hoie O, Aamodt G, Vermeire S, Bernklev T, Odes S, Wolters FL et al. Serological markers are associated with disease course in ulcerative colitis A study in an unselected population-based cohort followed for 10 years. J Crohn Colitis 2008;2:114-22. (Pubitemid 351672116)
37. Vecchi M, Bianchi MB, Calabresi C, Meucci G, Tatarella M, de Franchis R. Long-term observation of the perinuclear anti-neutrophil cytoplasmic antibody status in ulcerative colitis patients. Scand J Gastroenterol 1998;33:170-3. (Pubitemid 28098232)
38. Gabriel SE. The epidemiology of rheumatoid arthritis. Rheum Disclin North AM 2001;27:269-81. (Pubitemid 32488705)
39. Breedveld FC, Combe B. Understanding emerging treatment paradigms in rheumatoid arthritis. Arthritis Res Ther 2011;13(Suppl 1):S3.
40. Guidelines for the management of rheumatoid arthritis: 2002 Update Arthritis Rheum 2002;46:328-46.
41. Sizova L. Approaches to the treatment of early rheumatoid arthritis with disease-modifying antirheumatic drugs. Br J Clin Pharmacol 2008;66:173-8.
42. Quinn MA, Conaghan PG, Emery P The therapeutic approach of early intervention for rheumatoid arthritis: what is the evidence? Rheumatology (Oxford) 2001;40:1211-20.
43. Boers M, Verhoeven AC, Markusse HM, van de Laar MA, Westhovens R, van Denderen JC et al. Randomised comparison of combined step-down prednisolone, methotrexate and sulphasalazine with sulphasalazine alone in early rheumatoid arthritis. Lancet 1997;350:309-18. (Pubitemid 27351112)
44. Landewe RB, Boers M, Verhoeven AC, Westhovens R, van de Laar MA, Markusse HM et al. COBRA combination therapy in patients with early rheumatoid arthritis: long-term structural benefits of a brief intervention. Arthritis Rheum 2002;46:347-56. (Pubitemid 34136571)
45. Goekoop-Ruiterman YP, de Vries-Bouwstra JK, Allaart CF, van Zeben D, Kerstens PJ, Hazes JM et al. Clinical and radiographic outcomes of four different treatment strategies in patients with early rheumatoid arthritis (the BeSt study): A randomized, controlled triaL Arthritis Rheum 2008;58:S126-S135.
46. Lard LR, Visser H, Speyer I, vander Horst-Bruinsma IE, Zwinderman AH, Breedveld FC et aL Early versus delayed treatment in patients with recent-onset rheumatoid arthritis: comparison of two cohorts who received different treatment strategies Am.J.MeD 10-15-2001;111:446-51.
47. Nell VP, Machold KP, Eberl G, Stamm TA, Uffmann M, Smolen JS. Benefit of very early referral and very early therapy with disease-modifying anti-rheumatic drugs in patients with early rheumatoid arthritis. Rheumatology (Oxford) 2004;43:906-14. (Pubitemid 38996967)
48. van der Kooij SM, Ie Cessie S, Goekoop-Ruiterman YP, de Vries-Bouwstra JK, van Zeben D, Kerstens PJ et al. Clinical and radiological efficacy of initial vs delayed treatment with infliximab plus methotrexate in patients with early rheumatoid arthritis. Ann Rheum Dis 2009;68:1153-8.
49. Cohen G, Gossec L, Dougados M, Cantagrel A, Goupille P, Daures JP et al. Radiological damage in patients with rheumatoid arthritis on sustained remission. N Ann Rheum Dis 2007;66:358-63. (Pubitemid 46579638)
50. Molenaar ET, Voskuyl AE, Dinant HJ, Bezemer PD, Boers M, Dijkmans BA. Progression of radiologic damage in patients with rheumatoid arthritis in clinical remission. Arthritis Rheum 2004;50:36-42. (Pubitemid 38084285)
51. Redlich K, Hayer S, Ricci R, David JP, Tohidast-Akrad M, Kollias G et al. Osteoclasts are essential for TNF-alpha-mediated joint destruction. J Clin Invest 2002;110:1419-27. (Pubitemid 35396913)
52. Redlich K, Hayer S, Maier A, Dunstan CR, Tohidast-Akrad M, Lang S et al. Tumor necrosis factor alpha-mediated joint destruction is inhibited by targeting osteoclasts with osteoprotegeriN Arthritis Rheum 2002;46:785-92. (Pubitemid 34214261)
53. Smolen JS, Han C, Bala M, Maini RN, Kalden JR, van der Heijde D et al. Evidence of radiographic benefit of treatment with infliximab plus methotrexate in rheumatoid arthritis patients who had no clinical improvement: a detailed subanalysis of data from the anti-tumor necrosis factor trial in rheumatoid arthritis with concomitant therapy study. Arthritis Rheum 2005;52:1020-30. (Pubitemid 40530107)
54. Lipsky PE, van der Heijde DM, St Clair EW, Furst DE, Breedveld FC, Kalden JR et al. Infliximab and methotrexate in the treatment of rheumatoid arthritis Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. N Engl J Med 2000;343:1594-602.
55. Lakatos PL, Golovics PA, David G, Pandur T, Erdelyi Z, Horvath A et al. Has there been a change in the natural history of Crohn's disease? Surgical rates and medical management in a population-based inception cohort from Western Hungary between 1977-2009. Am J Gastroenterol 2012;107:579-88.
56. Ramadas AV, Gunesh S, Thomas GA, Williams GT, Hawthorne AB. Natural history of Crohn's disease in a population-based cohort from Cardiff (1986-2003): a study of changes in medical treatment and surgical resection rates. Gut 2010;59:1200-6.
57. Sans M, Lopez-San Roman A, Esteve M, Bermejo F, Garcia-Sanchez V, Torres Y. Early use of azathioprine has a steroid sparing effect on recently diagnosed Crohn's disease patients. Gastroenterology 2011;140:S109,A590.
58. Cosnes J, Bourrier A, Laharie D, Nahon S, Bouhnik Y, Carbonnel F et al. Early Administration of Azathioprine vs Conventional Management of Crohn's Disease: a Randomized Controlled TriaL Gastroenterology 2013 [Epub ahead of print].
59. D'Haens G, Baert F, Van Assche G, Caenepeel P, Vergauwe P, Tuynman H et al. Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn's disease: an open randomised trial. Lancet 2008;371:660-7. (Pubitemid 351284485)
60. Schreiber S, Reinisch W, Colombel JF, Sandborn WJ, Hommes DW, Robinson AM et al. Subgroup analysis of the placebo-controlled CHARM trial: increased remission rates through 3 years for adalimumab-treated patients with early Crohn's disease. J Crohn Colitis 2013;7:213-21.
61. Schreiber S, Colombel JF, Bloomfield R, Nikolaus S, Scholmerich J, Panes J et al. Increased response and remission rates in short-duration Crohn's disease with subcutaneous certolizumab pegol: an analysis of PRECiSE 2 randomized maintenance trial data. Am J Gastroenterol 2010;105:1574-82.
62. Moran G, Dubeau M, Kaplan G, Yang H, Seow C, Devlin S et al. Fibrostenotic disease behavior at the onset of biologic therapy is a predictor of poor outcomes. Gastroenterology 2012;142:S258, SA1267.
63. Colombel JF, Sandborn WJ, Reinisch W, Mantzaris GJ, Kornbluth A, Rachmilewitz D et al. Infliximab, azathioprine, or combination therapy for Crohn's disease. N Engl J Med 2010;362:1383-95.
64. Ferrante M, Vermeire S, Fidder H, Schnitzler F, Noman M, Van Assche G et al. Long-term outcome after infliximab for refractory ulcerative colitis J.CrohnSColitiS 2008;2:219-25.
65. Sandborn WJ, Van Assche G, Reinisch W, Colombel JF, D'Haens G, Wolf DC et al. Adalimumab induces and maintains clinical remission in patients with moderate-to-severe ulcerative colitis. Gastroenterology 2012;142:257-65.
66. Feagan B, Rutgeerts P, Sands B, Colombel J, Sandborn W, Hanaueur S. Induction therapy for ulcerative colitis: results of GEMINI I, a randomized, placebo-controlled, double-blind, multicenter phase 3 trial 2012;142.S160,A943b.
67. Colombel JF, Sandborn WJ, Rutgeerts P, Enns R, Hanauer SB, Panaccione R et al. Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial. Gastroenterology 2007;132:52-65. (Pubitemid 46108762)
68. Feagan BG, Panaccione R, Sandborn WJ, D'Haens GR, Schreiber S, Rutgeerts PJ et al. Effects of adalimumab therapy on incidence of hospitalization and surgery in Crohn's disease: results from the CHARM study. Gastroenterology 2008;135:1493-9.
69. Baert F, Moortgat L, Van Assche G, Caenepeel P, Vergauwe P, De Vos M et al. Mucosal healing predicts sustained clinical remission in patients with early-stage Crohn's disease. Gastroenterology 2010;138:463-8.
70. Schnitzler F, Fidder H, Ferrante M, Noman M, Arijs I, Van Assche G et al. Mucosal healing predicts long-term outcome of maintenance therapy with infliximab in Crohn's disease. Inflamm Bowel Dis 2009;15.1295-301.
71. Camus M, Seksik P, Bourrier A, Nion-Larmurier I, Sokol H, Baumer P et al. Long-term outcome of patients with Crohn's disease who respond to azathioprine. Clin Gastroenterol Hepatol 2013;11:389-94.
72. Laharie D, Filippi J, Roblin X, Nancey S, Chevaux JB, Hebuterne X et al. Impact of mucosal healing on long-term outcomes in ulcerative colitis treated with infliximab: a multicenter experience. Aliment Pharmacol Ther 2013;37:998-1004.
73. Bewtra M, Kaiser LM, TenHave T, Lewis J D Crohn's disease and ulcerative colitis are associated with elevated standardized mortality ratios: a meta-analysis. Inflamm Bowel Dis 2013;19:599-613.
74. Jess T, Frisch M, Simonsen J. Trends in overall and cause-specific mortality among patients with inflammatory bowel disease from 1982 to 2010. Clin Gastroenterol Hepatol 2013;11:43-8.
75. Lichtenstein GR, Rutgeerts P, Sandborn WJ, Sands BE, Diamond RH, Blank M et al. A pooled analysis of infections, malignancy, and mortality in infliximab- and immunomodulator-treated adult patients with inflammatory bowel disease. Am J Gastroenterol 2012;107:1051-63.
76. Kandiel A, Fraser AG, Korelitz BI, Brensinger C, Lewis JD. Increased risk of lymphoma among inflammatory bowel disease patients treated with azathioprine and 6-mercaptopurine. Gut 2005;54:1121-5. (Pubitemid 41025906)
77. Beaugerie L, Brousse N, Bouvier A, Colombel J, Lemann M, Cosnes J et al. Lymphoproliferative disorders in patients receiving thiopurines for inflammatory bowel disease: a prospective observational cohort study. Lancet 2009;374:1617-25.
78. Hanauer SB, Feagan BG, Lichtenstein GR, Mayer LF, Schreiber S, Colombel JF et al. Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet 2002;359:1541-9. (Pubitemid 34621118)
79. Rutgeerts P, Sandborn WJ, Feagan BG, Reinisch W, Olson A, Johanns J et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med 2005;353:2462-76. (Pubitemid 41770166)
80. Lichtenstein GR, Feagan BG, Cohen RD, Salzberg BA, Diamond RH, Price S et al. Serious infection and mortality in patients with Crohn's disease: more than 5 years of follow-up in the TREAT registry. Am J Gastroenterol 2012;107:1409-22.
81. Mackey AC, Green L, Leptak C, Avigan M. Hepatosplenic T cell lymphoma associated with infliximab use in young patients treated for inflammatory bowel disease: update. J Pediat. Gastroenterol Nutr 2009;48:386-8.